Association of a single‐nucleotide polymorphism in CD40 with the rate of joint destruction in rheumatoid arthritis

Objective The severity of joint destruction in rheumatoid arthritis (RA) is highly variable from patient to patient and is influenced by genetic factors. Genome‐wide association studies have enormously boosted the field of the genetics of RA susceptibility, but risk loci for RA severity remain poorl...

Full description

Saved in:
Bibliographic Details
Published inArthritis and rheumatism Vol. 60; no. 8; pp. 2242 - 2247
Main Authors van der Linden, Michael P. M., Feitsma, Anouk L., le Cessie, Saskia, Kern, Marlena, Olsson, Lina M., Raychaudhuri, Soumya, Begovich, Ann B., Chang, Monica, Catanese, Joseph J., Kurreeman, Fina A. S., van Nies, Jessica, van der Heijde, Désirée M., Gregersen, Peter K., Huizinga, Tom W. J., Toes, René E. M., van der Helm‐Van Mil, Annette H. M.
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.08.2009
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objective The severity of joint destruction in rheumatoid arthritis (RA) is highly variable from patient to patient and is influenced by genetic factors. Genome‐wide association studies have enormously boosted the field of the genetics of RA susceptibility, but risk loci for RA severity remain poorly defined. A recent meta‐analysis of genome‐wide association studies identified 6 genetic regions for susceptibility to autoantibody‐positive RA: CD40, KIF5A/PIP4K2C, CDK6, CCL21, PRKCQ, and MMEL1/TNFRSF14. The purpose of this study was to investigate whether these newly described genetic regions are associated with the rate of joint destruction. Methods RA patients enrolled in the Leiden Early Arthritis Clinic were studied (n = 563). Yearly radiographs were scored using the Sharp/van der Heijde method (median followup 5 years; maximum followup 9 years). The rate of joint destruction between genotype groups was compared using a linear mixed model, correcting for age, sex, and treatment strategies. A total of 393 anti–citrullinated protein antibody (ACPA)–positive RA patients from the North American Rheumatoid Arthritis Consortium (NARAC) who had radiographic data available were used for the replication study. Results The TT and CC/CG genotypes of 2 single‐nucleotide polymorphisms, rs4810485 (CD40) and rs42041 (CDK6), respectively, were associated with a higher rate of joint destruction in ACPA‐positive RA patients (P = 0.003 and P = 0.012, respectively), with rs4810485 being significant after Bonferroni correction for multiple testing. The association of the CD40 minor allele with the rate of radiographic progression was replicated in the NARAC cohort (P = 0.021). Conclusion A polymorphism in the CD40 locus is associated with the rate of joint destruction in patients with ACPA‐positive RA. Our findings provide one of the first non–HLA‐related genetic severity factors that has been replicated.
Bibliography:Dr. Begovich owns stock in Celera and stock options in Roche.
Dr. Gregersen has received consulting fees, speaking fees, and/or honoraria from Roche (less than $10,000). Ms Chang and Mr. Catanese own stock or stock options in Celera.
Dr. van der Linden and Ms Feitsma contributed equally to this work.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0004-3591
1529-0131
DOI:10.1002/art.24721